Abstract
Covid-19 has caused more than 1 million deaths in the US, including at least 1,088 deaths among children and young people (CYP) aged 0-19 years, with 764 occurring in the one year period April 1, 2021 - March 31, 2022. Deaths among US CYP are rare in general, and so we argue here that the mortality burden of Covid-19 in CYP is best understood in the context of all other causes of CYP death. Using publicly available data from CDC WONDER, and comparing to mortality in 2019, the immediate pre-pandemic period, we find that Covid-19 mortality is a leading cause of death in CYP aged 0-19 years in the US, ranking #8 among all causes of deaths, #5 in disease related causes of deaths (excluding accidents, assault and suicide), and #1 in deaths caused by infectious or respiratory diseases. Due to the impact of mitigations such as social distancing and our comparison of a single disease (Covid-19) to groups of causes such as deaths from pneumonia and influenza, these rankings are likely conservative lower bounds. Our findings underscore the public health relevance of Covid-19 to CYP. In the likely future context of sustained SARS-CoV-2 circulation, pharmaceutical and non-pharmaceutical interventions continue to play an important role in limiting transmission of the virus in CYP and mitigating severe disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ES and SF acknowledge funding from the EPSRC (EP/V002910/2), OR from the MRC (MR/V038109/1). SM and SB acknowledge funding from the Novo Nordisk Young Investigator Award (NNF20OC0059309). CW acknowledges funding from the MRC DTP that supports his PhD studies (Award Ref 1975152). This research was funded in whole or in part by EPSRC (EP/V002910/2). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript (AAM) version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY open available human data that were originally located at https://wonder.cdc.gov/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have fixed an error: our comparisons now use Covid-19 underlying cause of death data obtained from CDC Wonder. We have also simplified the comparison time periods.
Data Availability
All data were originally obtained from https://wonder.cdc.gov/ and are available online at https://github.com/flaxter/covid19pediatric/
